A
Autonomix Medical, Inc.
AMIXCIK 0001617867NasdaqNon-AcceleratedSmaller ReportingEmerging GrowthSurgical & Medical Instruments & ApparatusDelawareFY ends Mar 31
Period
FY 2025
Revenue
—
Net Income
$-11.40M
Total Assets
$9.81M
Equity
$8.10M
Shares Out
11.41M
Op. Cash Flow
$-8.30M
Business
Autonomix Medical, Inc. is a development-stage medical device company advancing a catheter-based, microchip-enabled sensing platform to detect and differentiate peripheral neural signals and enable targeted transvascular treatment. Its main offerings include a high-sensitivity sensing catheter with onboard microchip processing, radiofrequency (RF) ablation catheters, disposable handpieces and supporting software intended to sense, ablate and confirm nerve treatment. The company’s business is organized around diagnostic sensing and therapeutic RF ablation efforts, with plans to combine both into an integrated device and to leverage its patent portfolio. Autonomix targets hospital catheter labs and interventional radiology channels, pursuing clinical trials in Europe and regulatory pathways in the U.S. for commercialization to address pancreatic cancer pain and other peripheral nerve disorders globally.
Summary from filing dated 2025-05-29
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | Mar 31, 2026 2026-03-31 | Mar 31, 2025 2025-03-31 |
|---|---|---|---|
| Operating expenses: | — | — | |
| Research and development | 7 | 5 | |
| General and administrative | 10 | 7 | |
| Total operating expenses | 17 | 12 | |
| Loss from operations | −17 | −12 | |
| Other income (expense): | — | — | |
| Interest expense | 0 | 176,000 | |
| Interest income | 319,000 | 354,000 | |
| Total other income, net | 319,000 | 178,000 | |
| Loss before income taxes | −17 | −11 | |
| Income taxes | 0 | 0 | |
| Net loss | −17 | −11 | |
| Loss per share - basic and diluted (in dollars per share) | −2.32 | −6.46 | |
| Weighted average shares outstanding - basic and diluted (in shares) | 7 | 2 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | Mar 31, 2026 2026-03-31 | Mar 31, 2025 2025-03-31 |
|---|---|---|---|
| Current assets: | — | — | |
| Cash and cash equivalents | 7 | 9 | |
| Other current assets | 577,000 | 473,000 | |
| Total current assets | 8 | 10 | |
| Noncurrent assets: | — | — | |
| Property and equipment, net | 19,000 | 21,000 | |
| Deferred offering costs | 0 | 176,000 | |
| Total noncurrent assets | 19,000 | 197,000 | |
| Total Assets | 8 | 10 | |
| Current liabilities: | — | — | |
| Accounts payable | 700,000 | 676,000 | |
| Accrued expenses | 1 | 1 | |
| Total current liabilities | 2 | 2 | |
| Total Liabilities | 2 | 2 | |
| Commitments and contingencies (Note 4) | — | — | |
| Stockholders' equity: | — | — | |
| Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of March 31, 2026 and 2025, respectively | 0 | 0 | |
| Common stock, $0.001 par value, 500,000,000 shares authorized, 11,409,344 and 2,497,033 shares issued and outstanding as of March 31, 2026 and 2025, respectively | 11,000 | 2,000 | |
| Additional paid-in capital | 73 | 58 | |
| Accumulated deficit | −67 | −50 | |
| Total Stockholders' Equity | 6 | 8 | |
| Total Liabilities and Stockholders' Equity | 8 | 10 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | Mar 31, 2026 2026-03-31 | Mar 31, 2025 2025-03-31 |
|---|---|---|---|
| Cash Flows from Operating Activities: | — | — | |
| Net loss | −17 | −11 | |
| Adjustments to reconcile net loss to net cash used in operating activities: | — | — | |
| Stock-based compensation | 529,000 | 2 | |
| Stock option cancellations | 4 | 0 | |
| Issuance of common stock for equity line of credit commitment fee | 267,000 | 0 | |
| Depreciation and amortization expense | 12,000 | 183,000 | |
| Issuance of common stock, net of discount for lack of marketability | 0 | 101,000 | |
| Changes in operating assets - (increase)/decrease: | — | — | |
| Other current assets | 104,000 | −310,000 | |
| Changes in operating liabilities - increase/(decrease): | — | — | |
| Accounts payable | 24,000 | 184,000 | |
| Accrued expenses | −27,000 | 746,000 | |
| Net cash used in operating activities | −12 | −8 | |
| Cash Flows from Investing Activities: | — | — | |
| Purchase of property and equipment | 10,000 | 14,000 | |
| Net cash used in investing activities | −10,000 | −14,000 | |
| Cash Flows from Financing Activities (increase/decrease): | — | — | |
| Gross proceeds from issuance of common stock | 4 | 0 | |
| Direct financing costs for issuance of common stock | 141,000 | 0 | |
| Gross proceeds from warrant inducement | 3 | 0 | |
| Direct transaction costs for warrant inducement | 291,000 | 0 | |
| Gross proceeds from issuance and exercises of pre-funded warrants | 5 | 0 | |
| Direct financing costs for issuance of pre-funded warrants | 485,000 | 0 | |
| Gross proceeds from issuance of common stock, pre-funded and common warrants | 0 | 10 | |
| Direct transaction costs for issuance of common stock, pre-funded and common warrants | 0 | 1 | |
| Payment of issuance costs for registration statement | 0 | 176,000 | |
| Gross proceeds from exercise of warrants | 0 | 1,000 | |
| Proceeds from sales of common stock | 0 | 2,000 | |
| Net cash provided by financing activities | 10 | 9 | |
| Net change in cash and cash equivalents | −2 | 528,000 | |
| Cash and cash equivalents, at end of period | — | — | |
| Cash and cash equivalents, at end of period | — | — | |
| Non-cash financing activities: | — | — | |
| Recognition of deferred financing costs associated with issuance of common stock | −176,000 | 0 | |
| Proceeds from cashless exercise of warrants | 1,000 | 39,000 | |
| Warrants issued for equity issuance costs | 0 | 479,000 | |
| Convertible notes converted into common stock | 0 | 1 | |
| Settlement/conversion to common shares for debt issuance costs | 0 | −153,000 |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro